Akili, Inc. (AKLI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Akili, Inc. (AKLI) Healthcare & Pipeline Overview

Akili, Inc. pioneers digital therapeutics, developing physician-prescribed video game-based treatments like EndeavorRx for cognitive impairments, specifically attention function in children with ADHD. Based in Boston, the company leverages a novel approach to address neurological conditions within the evolving healthcare information services industry.

What Is the Investment Thesis for AKLI?

Akili, Inc. presents a unique investment profile centered on its pioneering role in prescription digital therapeutics (PDTs) with its FDA-cleared product, EndeavorRx. The company's core value driver is its innovative, non-pharmacological approach to treating cognitive impairments, starting with attention function in children with ADHD. The FDA clearance for EndeavorRx represents a significant regulatory hurdle overcome, validating the scientific rigor and clinical efficacy of its video game-based treatment. Potential growth catalysts include securing broader insurance reimbursement policies, which would significantly expand market access and adoption, and the potential for pipeline expansion into new therapeutic indications beyond ADHD. However, the company faces substantial challenges, as evidenced by its significant negative profit margin of -3545.5% and a market capitalization of $34.1M, indicating early-stage commercialization and high operational costs relative to revenue. Widespread physician and patient adoption, coupled with the establishment of clear reimbursement pathways, are critical for Akili to transition towards profitability. The company's high beta of 1.73 suggests higher volatility compared to the broader market, reflecting the inherent risks associated with a novel and evolving healthcare segment.

Based on FMP financials and quantitative analysis

AKLI Key Highlights

• Market capitalization stands at $0.03 billion, reflecting its status as an early-stage digital therapeutics company.
• The company reported a gross margin of 51.2%, indicating a solid margin on its product sales despite overall unprofitability.
• Akili's profit margin is significantly negative at -3545.5%, underscoring substantial operational expenses relative to its current revenue generation.
• The stock exhibits a Beta of 1.73, suggesting higher volatility and sensitivity to market movements compared to the broader market.
• Akili, Inc. currently employs 68 individuals, focusing on the development and commercialization of its digital therapeutic solutions.

Who Are AKLI's Competitors?

AKLI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AKLI's Key Strengths?

• FDA clearance for EndeavorRx, validating its efficacy as a medical device.
• Pioneering position in the emerging prescription digital therapeutics (PDT) market.
• Novel, engaging video game-based treatment approach for cognitive impairments.
• Proprietary technology platform with potential for broader therapeutic applications.

What Are AKLI's Weaknesses?

• Significant negative profit margin (-3545.5%), indicating high burn rate and early commercial stage.
• Challenges in securing widespread insurance reimbursement for digital therapeutics.
• Potential hurdles in achieving broad physician and patient adoption for a novel treatment modality.
• Relatively small market capitalization ($0.03B) and employee base (68), suggesting limited resources compared to large pharma.

What Could Drive AKLI Stock Higher?

• **Upcoming:** Potential for expanded insurance coverage and favorable reimbursement decisions for EndeavorRx from major payers, which would significantly improve market access.
• **Upcoming:** Announcement of new clinical trial initiations or positive data readouts for EndeavorRx in additional therapeutic indications beyond ADHD.
• **Ongoing:** Continued commercialization efforts for EndeavorRx, focusing on increasing physician prescriptions and patient adoption rates within the US market.
• **Upcoming:** Potential strategic partnerships or collaborations with pharmaceutical companies or healthcare systems to accelerate market penetration and product development.

What Are the Key Risks for AKLI?

• Financial-distress signal — its Altman Z-Score of -6.52 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-70.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• **Ongoing:** Significant financial losses, as indicated by a -3545.5% profit margin, posing a risk to sustained operations without further capital injection.
• **Potential:** Challenges in securing widespread and consistent insurance reimbursement for EndeavorRx, which could limit patient access and commercial growth.
• **Potential:** Slower-than-anticipated adoption of digital therapeutics by physicians and patients due to novelty, lack of awareness, or preference for traditional treatments.
• **Ongoing:** Intense competition from established pharmaceutical companies offering ADHD treatments, as well as other emerging digital health solutions.
• **Potential:** Regulatory hurdles or changes in the classification and oversight of prescription digital therapeutics, impacting future product development and market access.

What Are the Growth Opportunities for AKLI?

• **Expansion into New Therapeutic Indications:** Akili's underlying technology, designed to target cognitive function, possesses significant potential for application beyond ADHD. The company could pursue clinical development and regulatory clearance for its digital therapeutics in other neurological and psychiatric conditions, such as autism spectrum disorder, major depressive disorder, or early-stage Alzheimer's disease. Each new indication represents access to a distinct, large patient population, potentially unlocking substantial market opportunities. This expansion would leverage existing technological infrastructure and scientific expertise.
• **Geographic Market Expansion:** Currently focused in the US, Akili has the opportunity to expand the commercialization of EndeavorRx into international markets. Securing regulatory approvals and establishing distribution channels in key regions like Europe, Asia, or Canada would significantly broaden its addressable patient base. Each new market presents unique regulatory and reimbursement landscapes, requiring tailored strategies, but also offers access to millions of potential patients. For example, the European ADHD market alone represents a substantial patient pool, and successful market entry could substantially increase revenue streams over the next 3-5 years, diversifying the company's revenue geographically.
• **Securing Favorable Reimbursement Policies:** A critical growth driver for digital therapeutics is the establishment of widespread and favorable insurance reimbursement. Ongoing efforts to secure coverage from major public and private payers in the US are paramount. Successful negotiation of reimbursement codes and policies would significantly reduce out-of-pocket costs for patients and increase physician willingness to prescribe EndeavorRx. This would transform the commercial viability of the product, moving it from a niche offering to a more accessible treatment option. Progress in this area, potentially within the next 12-24 months, could unlock a much larger segment of the ADHD market and serve as a blueprint for future products.
• **Platform and Product Pipeline Development:** Beyond EndeavorRx, Akili can foster growth by investing in the development of its next generation of digital therapeutics or by enhancing its existing platform with new features, personalized adaptive algorithms, or companion diagnostics. A robust pipeline of clinically validated digital treatments for various cognitive challenges would establish Akili as a multi-product digital medicine company. This continuous innovation ensures long-term relevance and competitive advantage. The development of new modules or entirely new digital therapies, potentially targeting different age groups or specific cognitive domains, could open new revenue streams within a 3-7 year timeframe.
• **Strategic Partnerships and Collaborations:** Forming strategic alliances with pharmaceutical companies, large healthcare systems, or technology giants could accelerate Akili's market penetration and product development. Partnerships could involve co-development agreements for new indications, co-promotion efforts to expand physician awareness, or integration into broader digital health platforms. Collaborating with established players could provide access to larger sales forces, extensive patient networks, and valuable clinical insights, significantly de-risking commercialization efforts. Such collaborations, potentially materializing within the next 1-3 years, could provide capital, expertise, and distribution channels that are crucial for scaling a novel digital therapeutic.

What Opportunities Does AKLI Have?

• Expansion of EndeavorRx's indications to other cognitive impairments beyond ADHD.
• Geographic expansion into international markets to broaden patient reach.
• Advancements in digital health policy and reimbursement frameworks.
• Strategic partnerships with larger healthcare or technology companies for distribution and development.

What Threats Does AKLI Face?

• Intense competition from traditional pharmaceutical treatments for ADHD and other cognitive disorders.
• Regulatory changes or increased scrutiny on digital therapeutics.
• Slow adoption rates by healthcare providers and patients due to novelty or cost.
• Technological obsolescence or emergence of superior digital therapeutic platforms.

What Are AKLI's Competitive Advantages?

• **FDA Clearance:** EndeavorRx holds the distinction of being the first FDA-cleared prescription video game treatment for ADHD, providing a significant regulatory barrier to entry for competitors.
• **Proprietary Technology:** The company utilizes a unique, clinically validated technology platform that delivers targeted sensory stimuli to improve cognitive function, protected by intellectual property.
• **Clinical Validation:** Extensive clinical trials support the efficacy and safety of EndeavorRx, building trust and credibility within the medical community.
• **Novel Treatment Paradigm:** Akili is pioneering a new category of medicine, establishing early mover advantage and brand recognition in the emerging digital therapeutics space.

What Does AKLI Do?

Akili, Inc. is a digital medicine company headquartered in Boston, Massachusetts, dedicated to developing innovative digital therapeutics designed to address cognitive impairments. Founded on the premise that technology can directly impact neurological function, Akili has evolved to become a leader in the nascent field of prescription digital therapeutics (PDTs). The company's flagship product, EndeavorRx, exemplifies this pioneering approach. EndeavorRx is a physician-prescribed video game-based treatment specifically cleared by the FDA to improve attention function in children aged 8-12 with Attention-Deficit/Hyperactivity Disorder (ADHD), who have demonstrated an attention deficit. This unique therapeutic leverages a proprietary technology platform that delivers targeted sensory stimuli and motor challenges to activate specific neural systems in the brain, aiming to improve cognitive control. Akili's business model centers on creating clinically validated, engaging digital experiences that function as medical devices. The company's journey began with extensive research into neurocognition and the potential of digital interventions, culminating in the development and regulatory clearance of EndeavorRx, marking a significant milestone in digital healthcare. With a team of 68 employees, Akili focuses on bridging the gap between traditional pharmaceutical interventions and engaging digital experiences, positioning itself at the intersection of healthcare, technology, and gaming. The company's strategic focus involves not only the continued development and commercialization of EndeavorRx but also the exploration of its underlying technology for other cognitive conditions, aiming to expand its product pipeline and market reach within the broader medical-healthcare information services industry. Akili's approach represents a paradigm shift in how certain medical conditions, particularly those affecting cognitive function, can be treated, emphasizing non-pharmacological, evidence-based digital interventions.

What Products and Services Does AKLI Offer?

• Develops physician-prescribed digital therapeutics for cognitive impairments.
• Offers EndeavorRx, a video game-based treatment for attention function.
• Targets children aged 8-12 with ADHD who have demonstrated an attention deficit.
• Leverages a proprietary technology platform to deliver targeted neurological stimuli.
• Aims to improve cognitive control through engaging digital experiences.
• Focuses on clinically validated, FDA-cleared medical devices in digital format.
• Operates at the intersection of healthcare, technology, and gaming.

How Does AKLI Make Money?

• Generates revenue from the sale of its prescription digital therapeutic, EndeavorRx.
• Relies on physician prescriptions for its product, similar to traditional pharmaceuticals.
• Seeks insurance reimbursement for EndeavorRx to facilitate patient access and adoption.
• Potentially explores licensing agreements or partnerships for broader market reach and development.

What Industry Does AKLI Operate In?

Akili, Inc. operates within the dynamic Medical - Healthcare Information Services industry, specifically pioneering the emerging sub-segment of prescription digital therapeutics (PDTs). This industry is characterized by a growing demand for innovative, non-invasive, and data-driven healthcare solutions. Akili's position is unique, offering a physician-prescribed, FDA-cleared video game as a medical treatment, distinguishing it from general health and wellness apps. The broader market trend points towards increased adoption of digital health tools, driven by technological advancements, patient engagement, and the potential for cost-effective care. However, the PDT segment, while promising, is still in its infancy, facing hurdles such as establishing clear reimbursement pathways, gaining widespread physician acceptance, and ensuring patient adherence. Akili competes not only with other digital health companies but also indirectly with traditional pharmaceutical treatments for cognitive impairments. Its competitive edge lies in its FDA clearance and novel gamified approach, aiming to capture a share of the market for neurological and psychiatric conditions where digital interventions can offer a complementary or alternative treatment option.

Who Are AKLI's Key Customers?

• Children aged 8-12 diagnosed with ADHD and an attention deficit, as prescribed by a physician.
• Parents and guardians seeking non-pharmacological treatment options for their children's ADHD.
• Healthcare providers, including pediatricians, neurologists, and psychiatrists, who prescribe EndeavorRx.

ROE -70%Key Financial Metrics

Return on equity for Akili, Inc. stands at -70.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -74.0%, showing how much profit it generates from its asset base. A current ratio of 6.02 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -175.7%, the inverse of the P/E and a quick read on earnings relative to price.

Akili, Inc. (AKLI) Valuation Context

Valued at $34.1M, AKLI is classified as a micro-cap stock. Relative to its peer group, AKLI's quantitative score of 67/100 is roughly in line with the peer average of 63/100.

Company Profile

Akili, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Matthew Franklin. AKLI has traded publicly since 2021.

F-Score 3/9Financial Health

Akili, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.52 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Akili, Inc. revenue of about $8.5M for fiscal 2026, with EPS near $-0.47.

AKLI Financials

AKLI Latest News

No recent news available for AKLI.

AKLI Analyst Consensus

AKLI MoonshotScore

Akili, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources